Abstract:
Provided are a fly attractant composition containing a ligninsulfonate as an active ingredient, and a fly expellant composition containing 5 to 20% by weight of a ligninsulfonate and at least 0.1% by weight but less than 5% by weight of an insecticidal active ingredient.
Abstract:
The present invention relates to fungicidal compositions and their use for controlling oomycete pathogen induced disease or diseases in one or more plants.
Abstract:
The invention relates to insecticidal mixtures comprising, as active compounds, in each case two compounds from the series of the chloronicotinyl insecticides, and to the use of these mixtures for controlling animal pests.
Abstract:
An encapsulated composition of (a) a pesticide at least active via ingestion that is photolabile, and (b) at least one photoprotectant, wherein the encapsulating polymeric barrier is base triggerable is disclosed. A method for controlling damage of a material by a pest by the use of such encapsulated compositions is likewise disclosed. The composition as disclosed gives protection for beneficial arthropods and reduces workers exposure.
Abstract:
The invention relates to baits for controlling flies (fly gels) comprising a) one or more neonicotinoids, b) one or more gelling agents, c) one or more attractants, and having a gel point between having a Brookfield yield value between 150 and 1000 and a Brookfield viscosity between 40,000 and 150,000 mPa·s, to a process for the preparation of such fly gels, its use and methods for controlling flies.
Abstract:
Microbicidal compositions for the protection of industrial products and use in industrial or technical systems, comprising at least two different biocides selected from the group of active substances known as fungicides, insecticides, acaricides, or herbicides in the field of crop protection. Industrial materials comprising said mixture of biocides.
Abstract:
A method of inducing tolerance to a transplant transplanted from a donor to a subject is disclosed. The method comprises (a) restricting outflow of a fluid from a portion of the circulatory system of the subject; and (b) administering a dose of bone marrow cells derived from the donor to a body part delimiting said portion of the circulatory system, prior to, concomitantly with or following transplantation of the transplant, thereby inducing tolerance to the transplant in the subject.
Abstract:
The present application describes novel isoxazoline of formula I or II: or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, R1, R2, R3, R4, Z, U, X, Y, Za, and n are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-α converting enzyme (TACE), or a combination thereof.
Abstract translation:本申请描述了式I或II的新型异恶唑啉或其药学上可接受的盐或前药形式,其中A,R 1,R 2,R 3, R 4,Z 4,U,X,Y,Z a,以及n在本说明书中定义,其可用作基质金属蛋白酶抑制剂( MMP),TNF-α转化酶(TACE)或其组合。